Breast Cancer Unit, Radiation Oncology Department, Institute Gustave Roussy, Paris, France.
Clin Transl Oncol. 2011 Jul;13(7):446-50. doi: 10.1007/s12094-011-0681-2.
Radiochemotherapy is a standard approach in human solid tumours, with localised stage and radical treatment intention. In the early-intermediate stages of breast cancer model, neoadjuvant radiochemotherapy is an alternative to induction chemotherapy alone and might further impact the surgical technical treatment characteristics (a downsizing effect). In the era of targeted therapy and personalised treatment for breast cancer patients with initial localised disease, radiochemotherapy needs to be explored as a component of optimised local treatment to potentially improve relevant local results, such as breast conservation, breast cosmesis and individualised breast cancer radiochemotherapy response prediction. An overview of available literature data regarding neoadjuvant treatment including radiotherapy component is analysed and discussed.
放化疗是人类实体瘤的标准治疗方法,适用于局限性和根治性治疗目的。在乳腺癌早期-中期模型中,新辅助放化疗是单独诱导化疗的替代方案,并且可能进一步影响手术技术治疗特征(缩小效果)。在针对局部疾病初始患者的乳腺癌靶向治疗和个体化治疗时代,放化疗需要作为优化局部治疗的一部分进行探索,以潜在改善相关局部结果,如保乳、乳房美容和个体化乳腺癌放化疗反应预测。本文分析和讨论了有关新辅助治疗(包括放疗部分)的现有文献数据综述。